45
Participants
Start Date
April 4, 2007
Primary Completion Date
July 31, 2009
Study Completion Date
March 2, 2018
HKI-272
HKI-272 by mouth
trastuzumab
trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter
Fox Chase Cancer Center, Philadelphia
University of Maryland, University of Maryland Medical Center, Baltimore
Duke University, Duke University Medical Center, Durham
Centre Rene Gauducheau, Saint-Herblain
Institut Curie, Paris
LAC/USC Medical Center, USC/Norris Comprehensive Cancer Center, Los Angeles
City of Hope National Medical Center, Pasadena
Cancer Hospital, Academy of Med Science and Peking Union Med, Beijing
307 Hospital of Chinese People's Liberation Army, Beijing
Chinese PLA General Hospital, Beijing
Chinese Nanjing Bayi Hospital, Nanjing
Tianjin Union Medicine Center, Tianjin
City of Hope National Medical Center, Duarte
Centre Hospitalier Universitaire Vaudois, Lausanne
Puma Biotechnology, Inc.
INDUSTRY